cont...
✨Upa U-ACHIEVE maint
✨IL-23🧬
✨Delayed respndrs w risa in #CrohnsDisease
✨Miri & fatigue
✨VEGA combo tx study in UC
✨Upa vs Vedo 4 induction in #UlcerativeColitis

1️⃣#UEGWeek webinar 👇
2️⃣⏭Then watch Q&A👆⚙️Get the nuts & bolts on the data🔩

---
RT @MondayNightIBD
🙌 @my_ueg X #MondayNightIBD 🙌◦◦◦◦◦◦◦◦◦◦◦◦🎯 Best of #UEGWeek ◦◦◦◦ CME🔗http://bit.ly/MNIBD-UEG2022 ◦◦◦◦◦◦◦◦◦◦◦◦◦◦◦◦◦◦◦◦◦◦◦ Support by edu grants from @abbvie & B…
https://twitter.com/MondayNightIBD/status/1619349630994776065

#MondayNightIBD #GITwitter @my_ueg @BonumCe

⏮#ICYMI +replay full #webinar👇

🔦Top #IBD #UEGWeek abstracts🔦
✨Ozanimod True North extension study
✨ELEVATE-UC 12 & 52 of etrasimod
✨LADI ada dose interval study
✨Tofa RWE in #UlcerativeColitis
cont...👇

8/#MondayNightIBD #UEGWeek

👇#PostConvo #IBDPoll 4⃣
🟢The U-ACHIEVE Maintenance study, looked @ pts w UC who responded to induction tx w upadacitinib @ 8wks
Which tx group led to greater clinical remission per adapted Mayo score at wk 52 compared to PBO?

6/#MondayNightIBD #UEGWeek

👇#PostConvo #IBDPoll 2⃣
🟢Which drug combo were given in the Ph2a VEGA study to show the potential of dual inhibition of IL-23 & TNFα to more effectively induce CR & remission in pts w mod-sev UC?

7/#MondayNightIBD #UEGWeek

👇#PostConvo #IBDPoll 3⃣
🟢Which of the following PRO questionnaires assesses pt fatigue using a 13-item tool & 5-point scale, where a ⬆️higher score indicates a better pt outcome?

5/#MondayNightIBD #UEGWeek

👇#PostConvo #IBDPoll 1️⃣
🟢In the True North open-label extension, the findings indicated that approx 1/2 the pts who failed to achieve a CR after 10wks of ozanimod induction tx benefitted from which of the following:

#GITwitter #MondayNightIBD
⭐️⭐️⭐️NOW - Best of #IBD @ #UEGWeek Q&A w all-star faculty ⭐️⭐️⭐️
In collab w @my_ueg
TWEET your❓❓❓below ⬇️
Supported by edu grants from @abbvie & BMS⭐️⭐️⭐️

Join now w/ @CharlieMuz @DCharabaty @Iris_Dotan @MRegueiroMD

📲Tweet your❓below